$BKYI
BIO KEY INTERNATIONAL INC

2015 Q3 Form 10-Q Financial Statement

#000143774915020979 Filed on November 16, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q3
Revenue $669.8K $1.284M
YoY Change -47.83% 198.57%
Cost Of Revenue $374.8K $244.0K
YoY Change 53.65% 143.95%
Gross Profit $295.0K $1.040M
YoY Change -71.63% 215.12%
Gross Profit Margin 44.04% 81.0%
Selling, General & Admin $1.014M $989.5K
YoY Change 2.45% 33.72%
% of Gross Profit 343.65% 95.16%
Research & Development $368.8K $325.0K
YoY Change 13.48% -7.15%
% of Gross Profit 125.01% 31.25%
Depreciation & Amortization $10.00K $10.00K
YoY Change 0.0% 0.0%
% of Gross Profit 3.39% 0.96%
Operating Expenses $1.383M $1.315M
YoY Change 5.18% 19.5%
Operating Profit -$1.088M -$274.6K
YoY Change 296.02% -64.34%
Interest Expense $20.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net $7.976K $223.1K
YoY Change -96.42%
Pretax Income -$1.080M -$50.00K
YoY Change 2060.0% -93.59%
Income Tax $800.00
% Of Pretax Income
Net Earnings -$1.080M -$51.53K
YoY Change 1995.22% -93.39%
Net Earnings / Revenue -161.17% -4.01%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.565M -$83.33K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.00K $170.0K
YoY Change -58.82% -26.09%
Cash & Equivalents $72.23K $167.2K
Short-Term Investments
Other Short-Term Assets $80.00K
YoY Change 60.0%
Inventory $150.7K $10.00K
Prepaid Expenses
Receivables $2.165M $630.0K
Other Receivables $0.00 $20.00K
Total Short-Term Assets $2.426M $910.0K
YoY Change 166.59% 139.47%
LONG-TERM ASSETS
Property, Plant & Equipment $73.54K $100.0K
YoY Change -26.46% 233.33%
Goodwill
YoY Change
Intangibles $151.1K
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K
YoY Change 0.0% -90.0%
Total Long-Term Assets $233.4K $280.0K
YoY Change -16.65% -15.15%
TOTAL ASSETS
Total Short-Term Assets $2.426M $910.0K
Total Long-Term Assets $233.4K $280.0K
Total Assets $2.659M $1.190M
YoY Change 123.47% 67.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.308M $460.0K
YoY Change 184.34% 4.55%
Accrued Expenses $432.8K $480.0K
YoY Change -9.83% 17.07%
Deferred Revenue
YoY Change
Short-Term Debt $180.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.938M $1.370M
YoY Change 114.45% 18.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $80.00K
YoY Change
Total Long-Term Liabilities $0.00 $80.00K
YoY Change -100.0% -84.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.938M $1.370M
Total Long-Term Liabilities $0.00 $80.00K
Total Liabilities $2.938M $1.450M
YoY Change 102.62% -12.12%
SHAREHOLDERS EQUITY
Retained Earnings -$58.00M
YoY Change
Common Stock $6.607K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$278.7K -$260.0K
YoY Change
Total Liabilities & Shareholders Equity $2.659M $1.190M
YoY Change 123.47% 67.61%

Cashflow Statement

Concept 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$1.080M -$51.53K
YoY Change 1995.22% -93.39%
Depreciation, Depletion And Amortization $10.00K $10.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$460.0K -$350.0K
YoY Change 31.43% -56.79%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 250.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -460.0K -350.0K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 250.0K 0.000
Net Change In Cash -210.0K -350.0K
YoY Change -40.0% -369.23%
FREE CASH FLOW
Cash From Operating Activities -$460.0K -$350.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$460.0K -$350.0K
YoY Change 31.43% -56.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
CY2015Q3 bkyi Class Of Warrant Or Right Nonemployee Compensation Expense
ClassOfWarrantOrRightNonemployeeCompensationExpense
4398
bkyi Class Of Warrant Or Right Nonemployee Compensation Expense
ClassOfWarrantOrRightNonemployeeCompensationExpense
30054
CY2015Q1 bkyi Class Of Warrant Or Right Vesting Percentage
ClassOfWarrantOrRightVestingPercentage
0.01
CY2015Q3 bkyi Due To Factor
DueToFactor
572909
CY2014Q4 bkyi Due To Factor
DueToFactor
CY2015Q3 bkyi Factored Accounts Receivable Factored Amount
FactoredAccountsReceivableFactoredAmount
775598
CY2014Q4 bkyi Factored Accounts Receivable Factored Amount
FactoredAccountsReceivableFactoredAmount
229968
CY2015Q3 bkyi Factored Accounts Receivable Original Invoice Value
FactoredAccountsReceivableOriginalInvoiceValue
815085
CY2014Q4 bkyi Factored Accounts Receivable Original Invoice Value
FactoredAccountsReceivableOriginalInvoiceValue
306625
CY2011Q4 bkyi Factoring Arrangement Term
FactoringArrangementTerm
P2Y
bkyi Increase Decrease In Due To Factor
IncreaseDecreaseInDueToFactor
-533422
bkyi Increase Decrease In Due To Factor
IncreaseDecreaseInDueToFactor
bkyi Operational Costs
OperationalCosts
575000
CY2015Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
-533422
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
76657
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1307984
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
347311
CY2015Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2165416
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
625341
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
432793
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
488617
CY2015Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57719409
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57506605
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36050
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38064
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
258297
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
170282
CY2015Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
20526
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
20526
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
20000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
CY2015Q3 us-gaap Assets
Assets
2659346
CY2014Q4 us-gaap Assets
Assets
2067449
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10205
CY2015Q3 us-gaap Assets Current
AssetsCurrent
2425956
CY2014Q4 us-gaap Assets Current
AssetsCurrent
1793884
CY2015Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
233390
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10204
CY2014Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
273565
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="WIDTH: 36pt; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">1.</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">NATURE OF BUSINESS AND BASIS OF PRESENTATION</div></div></td> </tr> </table> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Nature of Business</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">BIO-key International, Inc. was founded in 1993 as a fingerprint biometric technology company. Biometric technology is the science of analyzing specific human characteristics which are unique to each individual in order to identify a specific person from a broader population. We develop and market advanced fingerprint biometric identification and identity verification technologies, cryptographic authentication-transaction security technologies, as well as related identity management and credentialing software solutions. We sell our products and provide services primarily to commercial entities within highly regulated industries, like healthcare and financial services and the broader corporate enterprise.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiary (collectively, the &#x201c;Company&#x201d;) and are stated in conformity with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Significant intercompany accounts and transactions have been eliminated in consolidation.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company&#x2019;s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December 31, 2014 was derived from the audited financial statements, but does not include all of the disclosures required by accounting principles generally accepted in the United States of America. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 (the &#x201c;Form 10-K&#x201d;), filed with the SEC on March 31, 2015.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Recently Issued Accounting Pronouncements</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 7.2pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In January 2015, ASU No. 2015-01, &#x201c;Income Statement &#x2013; Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary items&#x201d; (&#x201c;ASU 2015-01&#x201d;) was issued. ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. A reporting entity also may apply the amendments retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company is currently evaluating the effects of adopting ASU 2014-15 on its consolidated financial statements but the adoption is not expected to have a significant impact.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 7.2pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 7.2pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In April 2015, the FASB issued ASU 2015-03, &#x201c;Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.&#x201d; ASU 2015-03 requires debt issuance costs related to a debt liability measured at amortized cost to be reported in the balance sheet as a direct deduction from the face amount of the debt liability. ASU 2015-03 is effective for interim and annual periods beginning January 1, 2016 with early adoption permitted, and is applied on a retrospective basis. The adoption of ASU 2015-03 is not expected to materially impact the Company&#x2019;s consolidated financial statements.</div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In July 2015 the FASB issued ASU No. 2015-11, &quot;Inventory (Topic 330): Simplifying the Measurement of Inventory&quot; (&quot;ASU 2015-11&quot;). The amendments in ASU 2015-11 clarifies the measurement of inventory to be the lower of cost or realizable value and would only apply to inventory valued using the FIFO or average costing methods. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the effects of adopting ASU 2015-11 on its consolidated financial statements.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.</div></div></div>
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72232
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
843632
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2023349
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
167179
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-771400
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1856170
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.21
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
575000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66073482
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66001260
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66073482
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66001260
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
6607
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
6600
CY2015Q3 us-gaap Cost Of Revenue
CostOfRevenue
374840
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
243954
us-gaap Cost Of Revenue
CostOfRevenue
659590
us-gaap Cost Of Revenue
CostOfRevenue
522429
CY2015Q3 us-gaap Cost Of Services
CostOfServices
30283
CY2014Q3 us-gaap Cost Of Services
CostOfServices
144224
us-gaap Cost Of Services
CostOfServices
154251
us-gaap Cost Of Services
CostOfServices
296504
CY2015Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
92199
CY2014Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0
CY2015Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
392815
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
429233
CY2015Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8712
CY2014Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8712
us-gaap Depreciation
Depreciation
32049
us-gaap Depreciation
Depreciation
29905
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
27975
CY2014Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
223892
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
42228
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
117153
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
42228
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
117153
CY2015Q3 us-gaap Gross Profit
GrossProfit
295006
CY2014Q3 us-gaap Gross Profit
GrossProfit
1039893
us-gaap Gross Profit
GrossProfit
2931885
us-gaap Gross Profit
GrossProfit
2531729
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
912
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1712
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
960673
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-83634
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1540075
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
347549
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-55824
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
144216
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-36418
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-97057
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
138895
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2649
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-76657
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
19259
us-gaap Interest Expense
InterestExpense
20000
us-gaap Interest Expense
InterestExpense
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-198841
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7104
CY2015Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
151140
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
161344
CY2015Q3 us-gaap Interest Expense
InterestExpense
20000
CY2014Q3 us-gaap Interest Expense
InterestExpense
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2078
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9353
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-973836
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1696817
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-1079584
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-51526
CY2015Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1
CY2014Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5
us-gaap Interest Paid
InterestPaid
us-gaap Interest Paid
InterestPaid
CY2015Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
45239
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11825
CY2015Q3 us-gaap Inventory Net
InventoryNet
150720
CY2014Q4 us-gaap Inventory Net
InventoryNet
11825
CY2015Q3 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
105481
CY2014Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
92199
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2015Q3 us-gaap Liabilities
Liabilities
2938013
CY2014Q4 us-gaap Liabilities
Liabilities
1308388
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2659346
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2067449
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2938013
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1308388
CY2015Q3 us-gaap License Costs
LicenseCosts
344557
CY2014Q3 us-gaap License Costs
LicenseCosts
99730
us-gaap License Costs
LicenseCosts
505339
us-gaap License Costs
LicenseCosts
225925
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
204514
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-150000
us-gaap Net Income Loss
NetIncomeLoss
-1250539
us-gaap Net Income Loss
NetIncomeLoss
-1377026
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1079584
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-51526
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1250539
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1377026
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7976
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
223094
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21321
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
115446
CY2015Q3 us-gaap Notes Payable Current
NotesPayableCurrent
177801
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
1382566
CY2015Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
533422
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
6
CY2015Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
419655
CY2014Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
787720
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
2835662
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
2027089
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
1314513
us-gaap Operating Expenses
OperatingExpenses
4203745
us-gaap Operating Expenses
OperatingExpenses
4024201
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1087560
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-274620
us-gaap Operating Income Loss
OperatingIncomeLoss
-1271860
us-gaap Operating Income Loss
OperatingIncomeLoss
-1492472
CY2015Q3 us-gaap Other Assets Current
OtherAssetsCurrent
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
76657
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
150000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
58486
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2078
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9353
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
37588
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
236429
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
250000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73538
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
103509
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
368788
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
324992
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1169427
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1282536
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58004683
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56754144
CY2015Q3 us-gaap Revenues
Revenues
669846
CY2014Q3 us-gaap Revenues
Revenues
1283847
us-gaap Revenues
Revenues
3591475
us-gaap Revenues
Revenues
3054158
CY2015Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
250191
CY2014Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
496127
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
755813
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1027069
CY2015Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1013778
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
989521
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3034318
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2741665
us-gaap Share Based Compensation
ShareBasedCompensation
258297
us-gaap Share Based Compensation
ShareBasedCompensation
170282
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
13956250
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
-278667
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
759061
CY2015Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
93198
CY2014Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
43227
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66038941
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58026262
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66013958
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57989165

Files In Submission

Name View Source Status
0001437749-15-020979-index-headers.html Edgar Link pending
0001437749-15-020979-index.html Edgar Link pending
0001437749-15-020979.txt Edgar Link pending
0001437749-15-020979-xbrl.zip Edgar Link pending
bkyi-20150930.xml Edgar Link completed
bkyi-20150930.xsd Edgar Link pending
bkyi-20150930_cal.xml Edgar Link unprocessable
bkyi-20150930_def.xml Edgar Link unprocessable
bkyi-20150930_lab.xml Edgar Link unprocessable
bkyi-20150930_pre.xml Edgar Link unprocessable
bkyi20150930_10q.htm Edgar Link pending
ex10-1.htm Edgar Link pending
ex10-2.htm Edgar Link pending
ex3-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending